Finoriq research workspace
ADIAL PHARMACEUTICALS, INC. (ADIL) Historical Metrics
Review reported fundamentals, derived ratios, valuation context, and historical charts for ADIAL PHARMACEUTICALS, INC. (ADIL).
Company Snapshot
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
- Company
- ADIAL PHARMACEUTICALS, INC. (ADIL)
- Ticker
- ADIL
- Market Cap
- $5.9M
- Latest Price
- $2.73
- Industry
- Biotech & Pharma
ADIAL PHARMACEUTICALS, INC. (ADIL) Current Valuation Metrics
Static valuation preview for ADIAL PHARMACEUTICALS, INC. (ADIL). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -129.5% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -108.6% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.61x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.